Merck's third quarter earnings highlight a robust performance despite headwinds from generic competition and austerity measures, suggesting a positive short-term impact on stock prices. Key points include:
- Achieving solid growth in major products like JANUVIA, SINGULAIR, and REMICADE despite pricing pressures.
- On track to meet $3.5 billion in cost synergies by 2012, which supports profitability.
- A strong late-stage pipeline with data presentations on core products providing near-term catalysts.
- Guidance for 2010 has been slightly raised to $3.31-$3.39 EPS on a non-GAAP basis, reflecting confidence in underlying business performance.

The stock should see a positive movement in the next 1â€“2 weeks due to these factors.
[1]